1. Medtech Insight
  2. >>Business

Late-Stage Venture Continues To Dominate Medtech Financing

Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.

Device start-ups raised $1.7 billion in venture financing in 2013, a 31% drop from 2012’s $2.5 billion, despite only 11 fewer deals being signed in 2013. (See Exhibit 1.) The decrease isn’t surprising as venture investors continue to tighten their purse strings, according to a panel of corporate and institutional backers at the recent IN3Medical Device 360°Summit in San Francisco. (See Also see "Medtech VCs Find Ways To Fill The Gaps" - In Vivo, 25 February, 2014..)

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 
• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.